The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 10, 2022
Filed:
Mar. 03, 2016
Applicant:
Genzyme Corporation, Cambridge, MA (US);
Inventors:
Huawei Qiu, Bridgewater, NJ (US);
Julie Bird, Bridgewater, NJ (US);
Assignee:
Genzyme Corporation, Cambridge, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/22 (2006.01);
U.S. Cl.
CPC ...
C07K 16/22 (2013.01); A61K 39/3955 (2013.01); C07K 2317/14 (2013.01); C07K 2317/21 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/567 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract
A modified IgG antibody binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The modified IgG antibody comprises four polypeptide chains and may comprise modifications to the elbow regions of the polypeptide chains. The modified IgG antibody may comprise the same VH and VL domains or CDR regions as metelimumab. The modified IgG antibody is useful in therapeutic and diagnostic applications.